Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALOTHANE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Induction and maintenance of general anesthesia,Sedation in intensive care (off-label),Status asthmaticus (off-label, due to bronchodilation)
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Halothane is metabolized in the liver primarily by cytochrome P450 2E1 (CYP2E1) to trifluoroacetic acid and bromide ion; reductive metabolism also produces chloride ions and free radicals.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
Approximately 20-30% bound to plasma proteins, primarily albumin and lipoproteins.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
Volume of distribution at steady state (Vdss) approximately 2-5 L/kg; large Vd indicates extensive tissue distribution, especially to adipose tissue, brain, and muscle.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
100% bioavailable via inhalation (only route of administration). Oral bioavailability not applicable.
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
No specific dose adjustment required for renal impairment; use with caution due to potential nephrotoxicity from fluoride ions.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B and C: avoid use; contraindicated in patients with hepatic impairment or history of halothane-induced hepatotoxicity.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
Induction: 0.5-2% in oxygen or oxygen-nitrous oxide mixture, gradually increased; Maintenance: 0.3-1.5% as needed. Use lowest effective dose.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
Reduce dose by 25-50% due to increased sensitivity and reduced clearance; monitor hemodynamics closely.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
Halothane can cause hepatic necrosis, which may be fatal. Fatalities have occurred in patients with previous halothane exposure. Avoid repeat exposure within 3-6 months.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Hepatotoxicity (halothane hepatitis), malignant hyperthermia, cardiac arrhythmias (sensitizes myocardium to catecholamines), respiratory depression, hypotension, increased intracranial pressure.
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Hypersensitivity to halothane, known or suspected susceptibility to malignant hyperthermia, history of unexplained jaundice or fever after halothane, hepatic dysfunction following previous halothane exposure, pregnancy (relative, especially first trimester).
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
No specific food interactions. However, fasting is required before anesthesia to reduce aspiration risk. Alcohol should be avoided for at least 24 hours post-anesthesia due to additive CNS depression.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated with a potential increased risk of congenital malformations based on limited epidemiological data. Second and third trimester use may cause fetal depression and uterine atony; prolonged exposure can lead to neonatal respiratory depression. Avoid use during pregnancy unless clearly needed.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Halothane is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.4. Due to low oral bioavailability, risks to the nursing infant are minimal. However, caution is advised as effects on the infant have not been fully studied. Consider pumping and discarding milk for 24-48 hours after anesthesia to minimize exposure.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
No specific dose adjustment is recommended, but pregnancy alters pharmacokinetics: increased volume of distribution and decreased protein binding may require higher initial doses to achieve desired anesthetic depth. However, due to increased sensitivity to myocardial depression and uterine relaxation, use the minimum effective dose. Reduce concentration as needed to maintain uterine perfusion and avoid fetal hypoxia.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Halothane is a volatile halogenated hydrocarbon anesthetic. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias; avoid epinephrine use. Associated with halothane hepatitis (immune-mediated hepatotoxicity), especially with multiple exposures. Malignant hyperthermia trigger; have dantrolene ready. Use with caution in patients with increased intracranial pressure as it can elevate ICP. Use with low fresh gas flows to minimize pollution and cost.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
This medication will make you unconscious for surgery. You will not feel pain or remember the procedure.,You must fast before anesthesia; do not eat or drink for at least 6-8 hours before surgery.,Tell your anesthesiologist about any liver problems or previous reactions to anesthesia.,Notify your doctor if you have a personal or family history of malignant hyperthermia.,Avoid alcohol for at least 24 hours after anesthesia.,Do not drive or operate machinery for 24 hours after receiving halothane.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
"Efonidipine, a dihydropyridine calcium channel blocker, inhibits L-type and T-type calcium channels, leading to vasodilation and reduced myocardial contractility. Halothane, a volatile inhalational anesthetic, depresses myocardial function and sensitizes the myocardium to catecholamines, increasing the risk of arrhythmias. Concurrent use can result in additive negative inotropic effects and profound hypotension, potentially leading to cardiovascular collapse."
"Halothane, a volatile anesthetic, can inhibit the cytochrome P450 enzyme CYP2B6, which is primarily responsible for the metabolism of bupropion, an antidepressant and smoking cessation aid. This inhibition leads to decreased clearance of bupropion, resulting in elevated plasma concentrations that increase the risk of dose-dependent adverse effects such as seizures, anxiety, and insomnia. Clinically, patients may exhibit heightened neuropsychiatric toxicity and reduced seizure threshold, particularly during and after halothane anesthesia."
"Halothane, a volatile halogenated anesthetic, inhibits cytochrome P450 (CYP) isoenzymes, particularly CYP2C19, which is crucial for the hepatic bioactivation of clopidogrel to its active metabolite. Concomitant administration can lead to reduced plasma concentrations of the active thiol metabolite of clopidogrel, diminishing its antiplatelet effect and increasing the risk of thrombotic events such as stent thrombosis or myocardial infarction in patients with coronary artery disease. This interaction is especially significant in patients undergoing surgery where halothane is used for anesthesia while clopidogrel is indicated for recent acute coronary syndrome or percutaneous coronary intervention."
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALOTHANE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
HALOTHANE is a General Anesthetic that works by Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALOTHANE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALOTHANE is: Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALOTHANE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALOTHANE is classified as Category C. Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated w. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.